March 10, 2009
Devicor Medical Products Actively Seeking First Acquisition:

$250 million of committed equity capital immediately available to support growth strategy.

PLEASANT PRAIRIE, Wis.- March 10, 2009 - Tom Daulton, the former Cardinal Health executive recently tapped to head Devicor Medical Products, announced today that Devicor Medical Products is actively seeking its first acquisition as it begins building a market-leading medical device company in the highly attractive healthcare industry.

"With our strong, available capital we are actively pursuing a strategic acquisition to serve as Devicor Medical Products's platform," says Daulton.

Devicor Medical Products was created in partnership with GTCR Golder Rauner, LLC (GTCR), one of the nation's leading private equity firms, which initially committed $250 million of equity capital to support Devicor Medical Products's growth strategy. Daulton anticipates growing Devicor Medical Products into an industry-leading medical device company through a combination of capital investment, ongoing R&D investment, organic growth, and acquisitions.

Devicor Medical Products is currently looking to acquire established interventional medical device businesses that manufacture and sell products to clinicians in settings such as hospitals, surgery centers, or ambulatory clinics. Initial acquisitions are expected to provide infrastructure and personnel in key areas such as manufacturing, R&D, engineering, sales & marketing, finance, and human resources.

Daulton's career spans two decades in senior health care management roles at Baxter Healthcare, Allegiance Healthcare and Cardinal Health in both domestic and international positions. Most recently, Daulton served as General Manager of Cardinal's Interventional Specialties and Med Systems divisions, both fast-growing businesses, where he dramatically expanded revenue through a combination of organic growth, licensing and acquisitions.

“First and foremost, Devicor is a medical device company,” says Daulton. “The financial side of our business is critically important, and we’re enthusiastic about the number of compelling investment opportunities we see in the market. But, at the end of the day, we’re looking to advance the medical device industry and improve patient outcomes by building on something that works.”

<< Back